A Short-Acting GLP-1 Analog or Prandial Insulin to Supplement Basal Insulin?—Moving Toward Personalized Management of Type 2 Diabetes Mellitus

References

• . Auerbach DI, Liu H, Hussey PS, Lau C, Mehrotra A. Accountable care organization formation is associated with integrated systems but not high medical spending. Health Aff (Millwood). 2013;32(10):1781–1788
   PubMed Web of Science ®Google Scholar
• . Walker J, McKethan A. Achieving accountable care—“It's not about the bike.” N Engl J Med. 2012;366(2):e4
   Web of Science ®Google Scholar
• . Rosenbaum L. The whole ballgame—overcoming the blind spots in health care reform. N Engl J Med. 2013;368(10):959–962
   PubMed Web of Science ®Google Scholar
• . Cefalu WT. “TODAY” reflects on the changing “faces” of type 2 diabetes. Diabetes Care. 2013;36(6):1732–1734
   PubMed Web of Science ®Google Scholar
• . Kirkman MS, Briscoe VJ, Clark N, . Diabetes in older adults. Diabetes Care. 2012;35(12):2650–2664
   PubMed Web of Science ®Google Scholar
• . Porter ME. What is value in health care? N Engl J Med. 2010;363(26):2477–2481
   PubMed Web of Science ®Google Scholar
• . Lee TH. Putting the value framework to work. N Engl J Med. 2010;363(26):2481–2483
   PubMed Web of Science ®Google Scholar
• . Polinski JM, Smith BF, Curtis BH, . Barriers to insulin progression among patients with type 2 diabetes: a systematic review. Diabetes Educ. 2013;39(1):53–65
   PubMed Web of Science ®Google Scholar
• . Cuddihy RM, Philis-Tsimikas A, Nazeri A. Type 2 diabetes care and insulin intensification: is a more multidisciplinary approach needed? Results from the MODIFY survey. Diabetes Educ. 2011;37(1):111–123
   PubMed Web of Science ®Google Scholar
• . Cramer JA, Pugh MJ. The influence of insulin use on glycemic control: how well do adults follow prescriptions for insulin? Diabetes Care. 2005;28(1):78–83
   PubMed Web of Science ®Google Scholar
• . Hartz A, Kent S, James P, Xu Y, Kelly M, Daly J. Factors that influence improvement for patients with poorly controlled type 2 diabetes. Diabetes Res Clin Pract. 2006;74(3):227–232
   PubMed Web of Science ®Google Scholar
• . Donnelly LA, Morris AD, Evans JM; DARTS/MEMO collaboration. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM. 2007;100(6):345–350
   PubMed Web of Science ®Google Scholar
• . Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–3086
   PubMed Web of Science ®Google Scholar
• . Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29(6):1269–1274
   PubMed Web of Science ®Google Scholar
• . Holman RR, Farmer AJ, Davies MJ, . Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361(18):1736–1747
   PubMed Web of Science ®Google Scholar
• . Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomized controlled trial. Lancet. 2008;371(9618):1073–1084
   PubMed Web of Science ®Google Scholar
• . Little S, Shaw J, Home P. Hypoglycemia rates with basal insulin analogs. Diabetes Technol Ther. 2011;13( Suppl 1):S53–S64
   PubMed Web of Science ®Google Scholar
• . Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R; ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28(6):28:1282–1288
   PubMed Web of Science ®Google Scholar
• . Meneghini L, Koenen C, Weng W, Selam JL. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes—results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes Metab. 2007;9(6):902–913
   PubMed Web of Science ®Google Scholar
• . Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881–885
   PubMed Web of Science ®Google Scholar
• . LaSalle JR, Berria R. Insulin therapy in type 2 diabetes mellitus: a practical approach for primary care physicians and other health care professionals. J Am Osteopath Assoc. 2013;113(2):152–162
   PubMedGoogle Scholar
• . Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28(10):2543–2545
   PubMed Web of Science ®Google Scholar
• . Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):240–245
   PubMed Web of Science ®Google Scholar
• . Riddle MC, Karl DM. Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials. Diabetes Care. 2012;35(10):2100–2107
   PubMed Web of Science ®Google Scholar
• . Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29(5):682–689
   PubMed Web of Science ®Google Scholar
• . Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger P-M. Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetes Obes Metab. 2012;14(12):1081–1087
   PubMed Web of Science ®Google Scholar
• . Karter AJ, Subramanian U, Saha C, . Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 2010;33(4):733–735
   PubMed Web of Science ®Google Scholar
• . Peyrot M, Rubin RR, Lauritzen T, Snoek FJ, Matthews DR, Skovlund SE. Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med. 2005;22(10):1379–1385
   PubMed Web of Science ®Google Scholar
• . Snoek FJ, Skovlund SE, Pouwer F. Development and validation of the insulin treatment appraisal scale (ITAS) in patients with type 2 diabetes. Health Qual Life Outcomes. 2007;5:69
   PubMed Web of Science ®Google Scholar
• . Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118( Suppl 5 A):27S–34S
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE, Bergenstal RM, Buse JB, ; American Diabetes Association (ADA; European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379
   PubMed Web of Science ®Google Scholar
• . Riddle MC. A strategy for chronic disease. Lancet. 1980;2(8197):734–736
   PubMed Web of Science ®Google Scholar
• . Longworth DL. Accountable care organizations, the patient-centered medical home, and health care reform: what does it all mean? Cleveland Clinic J Med. 2011;78(9):571–582
   PubMed Web of Science ®Google Scholar
• . Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood).;2011;30(1):91–99
   PubMed Web of Science ®Google Scholar
• . Friedberg MW, Van Busum K, Wexler R, Bowen M, Schneider EC. A demonstration of shared decision making in primary care highlights barriers to adoption and potential remedies. Health Aff (Millwood). 2013;32(2):268–275
   PubMed Web of Science ®Google Scholar
• . Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26(10):2929–2940
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Heimesaat MM, Behle K, . Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87(3):1239–1246
   PubMed Web of Science ®Google Scholar
• . Buse JB, Bergenstal RM, Glass LC, . Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes; a randomized, controlled trial. Ann Intern Med. 2011;154(2):103–112
   PubMed Web of Science ®Google Scholar
• . Arnolds S, Dellweg S, Clair J, . Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care. 2010;33(7):1509–1515
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741–744
   PubMed Web of Science ®Google Scholar
• . Meier JJ, Gallwitz B, Salmen S, . Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(6):2719–2725
   PubMed Web of Science ®Google Scholar
• . Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2011
   Google Scholar
• . Victoza [package insert]. Princeton, NJ: Novo Nordisk, Inc; 2011
   Google Scholar
• . Gilbert MP, Pratley RE. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. Am J Med. 2009;122( Suppl 6):S11–S24
   Web of Science ®Google Scholar
• . Bischoff LA, Jabbour SA, Miller JL. Exenatide once weekly in type 2 diabetes mellitus. Expert Opin Pharmacother. 2011;12(8):1297–1303
   PubMed Web of Science ®Google Scholar
• . St Onge EL, Miller SA. Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes. Expert Opin Biol Ther. 2010;10(5):801–806
   PubMed Web of Science ®Google Scholar
• . Umpierrez GE, Blevins T, Rosentstock J, . The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab. 2011;13(5):418–425
   PubMed Web of Science ®Google Scholar
• . Christensen M, Knop FK, Vilsboll T, Holst JJ. Lixisenatide for type 2 diabetes mellitus. Expert Opin Investig Drugs. 2011;20(4):549–557
   PubMed Web of Science ®Google Scholar
• . Bydureon [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2012
   Google Scholar
• . Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728–742
   PubMed Web of Science ®Google Scholar
• . Jendle J, Martin SA, Milicevic Z. Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review. Expert Opin Investig Drugs. 2012;21(7):1463–1474
   PubMed Web of Science ®Google Scholar
• . Kapitza C, Forst T, Coester HV, Poitiers F, Ruus P, Hincelin-Mery A. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab. 2013;15(7):642–649
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561–1565
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Meier JJ. Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells? Nat Rev Endocrinol. 2011;7(4):193–195
   PubMed Web of Science ®Google Scholar
• . Tobin GS, Cavaghan MK, Hoogwerf BJ, McGill JB. Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy. Int J Clin Pract. 2012;66(12):1147–1157
   PubMed Web of Science ®Google Scholar
• . Fineman MS, Cirincione BB, Maggs D, Diamant M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab. 2012;14(8):675–688
   PubMed Web of Science ®Google Scholar
• . Seino Y, Min KW, Niemoeller E, Takami A; EFC10887 GETGOAL-L Asia Study Investigators. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012;14(10):910–917
   PubMed Web of Science ®Google Scholar
• . Riddle MC, Aronson R, Home, P, . Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013;36(9):2489–2496
   PubMed Web of Science ®Google Scholar
• . Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes. 2012;6(1):41–46
   PubMed Web of Science ®Google Scholar
• . Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther. 2009;31(7):1511–1523
   PubMed Web of Science ®Google Scholar
• . Thong KY, Jose B, Sukumar N, . Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit. Diabetes Obes Metab. 2011;13(8):703–710
   PubMed Web of Science ®Google Scholar
• . Ryder REJ, Thong KY, Cull ML, Mills A, Walter C, Winocour P. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Pract Diab Int. 2010;27(8):352b–357b
   Google Scholar
• . Thong KY, Jose B, Blann AD, . Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Diabetes Res Clin Pract. 2011;93(2):e87–e91
   Web of Science ®Google Scholar
• . Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534–539
   PubMed Web of Science ®Google Scholar
• . DeVries JH, Bain SC, Rodbard HW, . Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care. 2012;35(7):1446–1454
   PubMed Web of Science ®Google Scholar
• . Riddle M, Ahmann A, Basu A, Aroda V, Ratner R. Metformin + exenatide + basal insulin vs metformin + placebo + basal insulin: reaching A1C >6.5 without weight gain or serious hypoglycemia. Diabetes. 2010;59( Suppl 1A):LB6–LB18
   Google Scholar
• . Garber AJ. Novel GLP-1 receptor agonists for diabetes. Expert Opin Investig Drugs. 2012;21(1):45–57
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Germe M, Wang E, . Expanding the basal-plus regimen: basal + lixisenatide is more likely to achieve the composite outcome of HbA1c <7%, no documented symptomatic hypoglycemia and no weight gain compared with basal + prandial insulin. Poster (Abstract 1021-P) presented at 73rd Annual Scientific Sessions of the American Diabetes Association, June 21–25, 2013; Chicago, IL
   Google Scholar
• . Rosenstock J, Ahren BO, Chow FC, . Once-weekly GLP-1 receptor agonist albiglutide vs. titrated prandial lispro added on to titrated basal insulin glargine in type 2 diabetes (T2D) uncontrolled on glargine plus oral agents: similar glycemic control with weight loss and less hypoglycemia (Abstract). Diabetes. 2012;61( Suppl 1):A15
   Web of Science ®Google Scholar
• . Hirsch IB, Buse JB, Leahy J, . Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. Diabetes Obes Metab. 2013;16(3):206–214
   PubMed Web of Science ®Google Scholar
• . Vijan S, Hayward RA, Ronis DL, Hofer TP. Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered regimens. J Gen Intern Med. 2005;20(5):479–482
   PubMed Web of Science ®Google Scholar
• . Cleveringa FG, Gorter KJ, van den Donk M, van Gijsel J, Rutten GE. Computerized decision support systems in primary care for type 2 diabetes patients only improve patients' outcomes when combined with feedback on performance and case management: a systematic review. Diabetes Technol Ther. 2013;15(2):180–192
   PubMed Web of Science ®Google Scholar
• . Elwyn G, Frosch D, Volandes AE, Edwards A, Montori VM. Investing in deliberation: a definition and classification of decision support interventions for people facing difficult health decisions. Med Decis Making. 2010;30(6):701–711
   PubMed Web of Science ®Google Scholar
• . Breslin M, Mullan RJ, Montori VM. The design of a decision aid about diabetes medications for use during consultation with patients with type 2 diabetes. Patient Educ Couns. 2008;73(3):465–472
   PubMed Web of Science ®Google Scholar
• . Peyrot M, Rubin RR. Behavioral and psychosocial interventions in diabetes: a conceptual review. Diabetes Care. 2007;30(10):2433–2440
   PubMed Web of Science ®Google Scholar
• . Murray E, Burns J, See TS, Lai R, Nazareth I. Interactive health communication applications for people with chronic disease. Cochrane Database Syst Rev. 2005;19(4):CD004274
   Web of Science ®Google Scholar
• . Picker Institute Europe (2010). Invest in engagement. Picker Institute. www.investinengagement.info. Accessed October 25, 2013
   Google Scholar
• . Centers for Disease Control and Prevention. Well-being concepts. http://www.cdc.gov/hrqol/wellbeing.htm. Accessed October 25, 2013
   Google Scholar
• . Raz I, Riddle MC, Rosenstock J, . Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care. 2013;36(11):1779–1788
   PubMed Web of Science ®Google Scholar
• . Altschuler J, Margolius D, Bodenheimer T, Grumbach K. Estimating a reasonable patient panel size for primary care physicians with team-based task delegation. Ann Fam Med. 2012;10(5):396–400
   PubMed Web of Science ®Google Scholar
• . Reid RJ, Coleman K, Johnson EA, . The Group Health medical home at year two: cost savings, higher patient satisfaction, and less burnout for providers. Health Aff (Millwood). 2010;29(5):835–843
   PubMed Web of Science ®Google Scholar
• . Gabbay RA, Friedberg MW, Miller-Day M, Cronholm PF, Adelman A, Schneider EC. A positive deviance approach to understanding key features to improving diabetes care in the medical home. Ann Fam Med. 2013;11( Suppl 1):S99–S107
   PubMed Web of Science ®Google Scholar
• . Ludwick DA, Doucette J. Adopting electronic medical records in primary care: lessons learned from health information systems implementation experience in seven countries. Int J Med Inform. 2009;78(1):22–31
   PubMed Web of Science ®Google Scholar
• . Terry K. Healthcare workaround expose EHR flaws. Information Week. http://www.informationweek.com/healthcare/electronic-medical-records/healthcare-workarounds-expose-ehr-flaws/240151710. Accessed March 26, 2013
   Google Scholar
• . Sox HC, Greenfield S. Comparative effectiveness research: A report from the Institute of Medicine. Ann Intern Med. 2009;151(3):203–205
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Buse JB, Kahn SE, . Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2013;36(8):2254–2261
   PubMed Web of Science ®Google Scholar
• . T1D Exchange. http://t1dxregistry.jaeb.org/. Accessed October 30, 2013
   Google Scholar
• . Patient-Centered Outcomes Research Institute. http://www.pcori.org/about-us/landing/. Accessed October 30, 2013
   Google Scholar
• . Summary of 2015 Physician Value-based Payment Modifier Policies. www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/Downloads/CY2015ValueModifierPolicies.pdf. Accessed December 10, 2013
   Google Scholar
• . O'Connor PJ, Bodkin NL, Fradkin J, . Diabetes performance measures: current status and future directions. Diabetes Care. 2011;34(7):1651–1659
   PubMed Web of Science ®Google Scholar